Alkermes stock price target raised to $47 from $45 at RBC Capital
PositiveFinancial Markets

Alkermes has received a boost in its stock price target, now set at $47, up from $45, according to RBC Capital. This increase reflects growing confidence in the company's future performance and potential for growth, which is significant for investors looking for promising opportunities in the pharmaceutical sector.
— Curated by the World Pulse Now AI Editorial System